Intra-Cellular Therapies Aktie
WKN DE: A1XDTL / ISIN: US46116X1019
03.11.2014 13:27:00
|
Intra-Cellular Therapies Q3 Loss Widens - Quick Facts
(RTTNews) - Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, reported a third-quarter net loss of $6.4 million, or $0.22 per share, compared to a net loss of $4.9 million, or $0.28 per share, for the third quarter of 2013.
Revenues were $124 thousand, compared to $668 thousand, last year. Research and development expenses for the third quarter of 2014 were $4.0 million, compared to $4.2 million for the third quarter of 2013.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Intra-Cellular Therapies Incmehr Nachrichten
29.10.24 |
Ausblick: Intra-Cellular Therapies öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Intra-Cellular Therapies Incmehr Analysen
Aktien in diesem Artikel
Intra-Cellular Therapies Inc | 122,00 | 0,83% |
|